Welcome to our dedicated page for HYPERFINE SEC filings (Ticker: HYPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Hyperfine, Inc. (Nasdaq: HYPR), a health technology and medical device company in the electromedical and electrotherapeutic apparatus manufacturing industry. Hyperfine’s filings offer detailed information on its portable, ultra-low-field brain MRI business built around the Swoop® Portable MR Imaging® System and related AI-powered software.
Investors can use Hyperfine’s periodic reports and current reports to understand the company’s financial condition, capital structure, and key business developments. Form 8-K filings, for example, have disclosed quarterly financial results, preliminary unaudited revenue and cash figures, business highlights related to the commercial rollout of the next generation Swoop® system and Optive AI™ software, and information about underwritten public offerings of Class A common stock. One 8-K also documents that Hyperfine regained compliance with Nasdaq’s minimum bid price requirement, providing context on its listing status.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available on this page) typically include more extensive discussions of revenue sources from MRI device sales and service sales, research and development spending, risk factors, and details on regulatory clearances and market access for the Swoop® system. Filings related to securities offerings, such as the underwriting agreement described in an October 16, 2025 Form 8-K, outline terms of equity raises and associated use of proceeds.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information about revenue trends, cash position, and material agreements. Real-time updates from EDGAR ensure that new Hyperfine filings, including Forms 10-K, 10-Q, 8-K, and ownership-related filings such as Form 4 when available, are added promptly. This makes the HYPR SEC filings page a focused resource for analyzing Hyperfine’s regulatory disclosures, capital markets activity, and evolving business around portable brain MRI technology.
Hyperfine, Inc. (HYPR) reporting person Thomas Teisseyre, Chief Operating Officer and Director, reported a sale of Class A common stock on 08/18/2025. The Form 4 shows 1,151 shares were sold at $1.33 per share to satisfy tax withholding obligations tied to restricted stock units granted on March 28, 2022 and April 28, 2022. After the reported sale, Mr. Teisseyre beneficially owned 381,062 shares. The sale was executed under a "sell to cover" provision in the RSU agreement and the form was signed by an attorney-in-fact.
Hyperfine, Inc. furnished a press release announcing results for the second quarter ended June 30, 2025 and provided a business update; the press release is attached as Exhibit 99.1 to this Form 8-K.
The filing states the furnished material is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference. The company lists its Class A common stock (HYPR) on The Nasdaq Stock Market and indicates it is an emerging growth company. The report is signed by Brett Hale in his capacities as Chief Administrative Officer and Chief Financial Officer.
Hyperfine, Inc. (HYPR) received a Nasdaq notice on April 30, 2025 that its closing bid price fell below the $1.00 minimum for 30 consecutive business days and therefore did not meet Nasdaq Listing Rule 5450(a)(1). On August 6, 2025, Nasdaq notified the Company that it has regained compliance with the bid-price requirement and the matter is closed.
Key facts:
- Nasdaq deficiency notice: April 30, 2025
- Regained compliance and matter closed: August 6, 2025
- Ticker: HYPR; security: Class A common stock on the Nasdaq Global Market